Monoclonal Antibody News and Research

RSS
Monoclonal antibodies (MAbs) are produced from a single B cell clone and can bind to a single type of antigen binding site. MAbs are homogenous antibodies that cannot form lattices with monomeric proteins as they can bind to only a single epitope on the antigen. Developed in the 1970s, MAbs can be produced against any given substance. Thus they can be used to detect and purify any substance of interest. This has made MAbs a powerful tool of molecular biology, biochemistry, and medicine.
Evidence that monoclonal antibodies can reduce COVID-19 (Delta) mortality

Evidence that monoclonal antibodies can reduce COVID-19 (Delta) mortality

Efficacy and safety of mRNA-based SARS-CoV-2 vaccination in immuno-compromised subjects

Efficacy and safety of mRNA-based SARS-CoV-2 vaccination in immuno-compromised subjects

WHO's recommendation provides two new options for treating COVID-19

WHO's recommendation provides two new options for treating COVID-19

Rapid antigen test for SARS-CoV-2 proves to be highly accurate for pediatric populations

Rapid antigen test for SARS-CoV-2 proves to be highly accurate for pediatric populations

A clinical tool for monoclonal antibody allocation to treat COVID-19

A clinical tool for monoclonal antibody allocation to treat COVID-19

Providing recombinant antibody services and more within Europe

Providing recombinant antibody services and more within Europe

Optimal monoclonal antibodies against SARS-CoV-2 variants

Optimal monoclonal antibodies against SARS-CoV-2 variants

SARS-CoV-2 Delta sublineage AY.4.2 shows no increase in cell entry or antibody evasion

SARS-CoV-2 Delta sublineage AY.4.2 shows no increase in cell entry or antibody evasion

Scientists discover antibody that inhibits a broad range of sarbecoviruses

Scientists discover antibody that inhibits a broad range of sarbecoviruses

Big Tuna and automated buffer exchange: An interview with Unchained Labs

Big Tuna and automated buffer exchange: An interview with Unchained Labs

Researchers create new monoclonal antibody treatment effective against both Delta and Omicron

Researchers create new monoclonal antibody treatment effective against both Delta and Omicron

Serological antibody response to SARS-CoV-2 infection at a population level

Serological antibody response to SARS-CoV-2 infection at a population level

LIVE-AIR trial demonstrates efficacy of Lenzilumab for treatment of COVID patients with decreased oxygen saturation

LIVE-AIR trial demonstrates efficacy of Lenzilumab for treatment of COVID patients with decreased oxygen saturation

Booster dose elicits cross-reactive humoral immunity against SARS-CoV-2 Delta and Omicron variants

Booster dose elicits cross-reactive humoral immunity against SARS-CoV-2 Delta and Omicron variants

Monoclonal antibody treatment of COVID-19 reduces viral shedding

Monoclonal antibody treatment of COVID-19 reduces viral shedding

Folic acid-like drug reprograms DNA methylome of aggressive brain tumors

Folic acid-like drug reprograms DNA methylome of aggressive brain tumors

Efficacy of COVID-19 convalescent plasma therapy in patients with hematological malignancies and COVID-19

Efficacy of COVID-19 convalescent plasma therapy in patients with hematological malignancies and COVID-19

Study finds pan-sarbecovirus nanobodies can enhance development of super-immunity

Study finds pan-sarbecovirus nanobodies can enhance development of super-immunity

Sino Biological Establishes New Location in Houston, Texas

Sino Biological Establishes New Location in Houston, Texas

SARS-CoV-2 Omicron variant highly resistant to vaccine-elicited and therapeutic antibodies

SARS-CoV-2 Omicron variant highly resistant to vaccine-elicited and therapeutic antibodies